AAV Capsid Peptide Inserts for Brain and Muscle Tropism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current AAV capsids exhibit low transduction efficiency and are neutralized by pre-existing antibodies, limiting their effectiveness in delivering payloads to target cells, particularly in the CNS and muscle tissues.
Innovation Solution
Development of AAV capsid variants with enhanced tropism, achieved by inserting specific peptides at defined positions in the capsid structure, such as loop VIII, to improve targeting to CNS and muscle tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural AAV capsids are used for gene delivery, then the vector is non-pathogenic and has low immunogenicity, but the transduction efficiency in certain organs is too low for clinical applications
Solution Approach 1:
The patent applies parameter changes by systematically mutating specific amino acid positions in the AAV capsid sequence (positions 586-589 and surrounding regions) to alter capsid properties. These targeted mutations modify the capsid's interaction with target cells while preserving the overall safety profile, thereby improving transduction efficiency in CNS and muscle tissues without compromising the non-pathogenic nature of the vector.
Solution Approach 2:
The patent implements local quality by introducing targeted peptide inserts or mutations at specific localized regions of the capsid structure (such as loop VIII and positions adjacent to 586-589). This localized modification allows the capsid to gain enhanced tropism for specific tissues while maintaining the safety characteristics of the overall vector structure.
2Reliability
If AAV capsids are used for payload delivery, then the vector has low immunogenicity and low integration rate, but pre-existing neutralizing antibodies may prevent treatment of a large proportion of patients
Solution Approach 1:
The patent uses parameter changes by mutating specific capsid amino acid sequences to create variants that have altered epitope structures. These mutations reduce recognition by pre-existing neutralizing antibodies while maintaining the vector's low immunogenicity profile, thereby expanding the pool of eligible patients who can receive treatment.
Solution Approach 2:
The patent employs composite materials by combining the AAV capsid structure with engineered peptide inserts or mutated regions that provide both neutralization resistance and tissue-specific tropism. This composite approach allows the vector to evade neutralizing antibodies while maintaining safety characteristics.
3Productivity
If AAV capsid sequence randomization is performed to create variants, then new capsid variants with enhanced properties can be obtained, but the complexity of capsid engineering increases
Solution Approach 1:
The patent applies segmentation by dividing the capsid engineering process into specific targeted regions (such as loop VIII and positions 586-589) rather than randomizing the entire capsid sequence. This segmented approach focuses mutations on critical regions known to influence tropism and neutralization, thereby reducing the complexity of engineering while still generating useful variants.
Solution Approach 2:
The patent implements preliminary action by pre-identifying and pre-mutating specific capsid positions (586-589 and surrounding regions) that are most likely to influence tissue tropism and neutralization resistance. This preliminary focus on high-impact regions streamlines the variant generation process and reduces overall engineering complexity.
Data Source
AI summary
The disclosure relates to compositions, methods, and processes for the preparation, use, and/or formulation of adeno-associated virus capsid proteins, wherein the capsid proteins comprise targeting peptide inserts for enhanced tropism to a target tissue.